When: Below $66.20 (no adds above this level)

Then: Entry threshold for potential adds

HOLD

• Forward P/E of 9.7 times is discounted for reasons including Eliquis losing exclusivity between 2026 and 2027, Revlimid eroding under generic pressure, $45 billion in total debt against $22 billion in equity, and nearly $40 billion in goodwill and intangibles
• The 17.75 PEG ratio reflects five years of flat revenue representing the reality of a maturing portfolio in transition, not flawed modeling
• Institutional distribution before arlo-cel binary catalyst represents de-risking behavior to protect gains from a year-to-date run of nearly 20 percent, not accumulation
• Cytokinetics patent dispute where RBC explicitly sided against BMY represents a concrete legal overhang that could impair near-term value from omecamtiv mecarbil
• Technical momentum has broken down with MACD crossing bearish, RSI falling from 69 to 42 in 17 sessions, and stock testing the Bollinger lower band with only 0.7 percent buffer
• Beta of 0.23 indicates correlation, not immunity—BMY dropped 30 percent in 2024 on acquisition impairments despite low beta
• Conservative stop at 61.80 caps downside at approximately 3 percent of position value versus aggressive stop at 58.50 which absorbs a nearly 10 percent drawdown
• Downside scenario could push stock toward the 52-week low of 42, representing a 34 percent loss from current levels, unbounded by technical support

→ vs aggressive: The 'screaming value' framing at 9.7 times forward earnings ignores that the market is pricing in a multi-year revenue cliff from patent expirations and generic erosion, not offering a gift

→ vs aggressive: The arlo-cel institutional accumulation thesis is inverted—professional institutions de-risk before binary events, and the year-to-date 20 percent run suggests profit-taking behavior rather than smart money positioning

→ vs aggressive: The Cytokinetics patent dispute where RBC sided against BMY is an active legal proceeding representing concrete downside risk that the aggressive analyst glossed over

→ vs aggressive: The aggressive stop at 58.50, nearly 10 percent below entry, accepts a double-digit drawdown that could wipe out more than two years of dividend income—unacceptable for a defensive pharma mandate

→ vs aggressive: The asymmetric payoff math overstates upside while the downside scenario is unbounded by technical support levels; a 52-week low of 42 represents a 34 percent loss that contradicts the 'asymmetric' characterization

→ vs aggressive: Low beta does not provide immunity from losses—BMY dropped 30 percent in 2024 despite 0.23 beta, as beta measures correlation, not downside protection

Maintain existing position and prepare a two-tranche scale-in plan: modest add at 50 SMA (63.43), second tranche on confirmed defense of 61.80 to 63.00 zone; stop at 60.50 to 61.00; target exit at 68 for new tranches

• 50 SMA at 63.43 is natural entry zone for modest partial tranche add
• Second tranche only on confirmed defense of 61.80 to 63.00 zone
• If close below 61.80 on volume, do not add positions
• Honest stop is 60.50 to 61.00 (below Bollinger lower band, appropriate for 4% risk on position)
• Target exit for new tranches at prior high 68, not 70 (requires multiple expansion difficult in Fed hike environment)
• 9.7x forward P/E represents margin of safety, not a value trap; FCF yield and dividend provide return floor
• Arlo-cel Phase 2 data already digested; catalyst risk is ambiguous binary (share gain vs. CAR-T class sentiment damage)
• Long-term uptrend intact with 200 SMA rising to 57.69, 50 SMA above it
• Macro backdrop of 94% odds of zero 2026 Fed cuts limits multiple expansion potential

→ vs aggressive: FCF yield framing inconsistent with dismissing PEG of 17.75; cannot claim screaming value while rejecting valuation metrics

→ vs aggressive: Asymmetric payoff math undersized: 10% downside scenario too small given BMY fell 30% in 2024 on idiosyncratic news despite 0.23 beta; patent cliff with LOE dynamics is a correlated stack, not single-variable tail

→ vs aggressive: Institutional distribution argument flawed: institutions de-risk before binary catalysts because 30% gap-down versus 10% gap-up asymmetry is unfavorable, not because they're afraid of being early

→ vs aggressive: Price action shows distribution not accumulation: six straight down sessions from 68 to 63 with accelerating MACD histogram downside

→ vs aggressive: 8 to 10 percent stops on 52-week low of 42 is too loose given actual downside risk profile; not risk management, just hoping to be right

→ vs conservative: 6.5% pullback in 0.23 beta name is routine mean-reversion within larger uptrend, not regime change; long-term uptrend unambiguously intact

→ vs conservative: 61.80 stop too tight given ATR of only 1.45; will get triggered by ordinary volatility and shake out position right before bounce

→ vs conservative: Dismissing valuation entirely is wrong: 9.7x forward earnings is margin of safety; if market wrong on LOE impact, re-rating delivers upside; if market right, dividend and FCF provide return floor

→ vs conservative: Conservative discipline is self-defeating on low-beta defensive name where natural volatility band encompasses the stop level